Former Associated Press journalist and newsroom leader Paul Driscoll has died at the age of 91. Driscoll covered the civil ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

Lindsey Twardak is a woman under 50 and a breast cancer survivor. "It's really important to understand that cancer does not ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...